WO2012144784A3 - 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 - Google Patents

인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 Download PDF

Info

Publication number
WO2012144784A3
WO2012144784A3 PCT/KR2012/002911 KR2012002911W WO2012144784A3 WO 2012144784 A3 WO2012144784 A3 WO 2012144784A3 KR 2012002911 W KR2012002911 W KR 2012002911W WO 2012144784 A3 WO2012144784 A3 WO 2012144784A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
carboxylesterase
human liver
cell lines
hybridoma cell
Prior art date
Application number
PCT/KR2012/002911
Other languages
English (en)
French (fr)
Other versions
WO2012144784A2 (ko
Inventor
백융기
나근
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to US14/112,411 priority Critical patent/US9116152B2/en
Priority to JP2014506322A priority patent/JP5798679B2/ja
Priority to CN201280029813.2A priority patent/CN104066749B/zh
Priority to EP12774256.7A priority patent/EP2700650B1/en
Publication of WO2012144784A2 publication Critical patent/WO2012144784A2/ko
Publication of WO2012144784A3 publication Critical patent/WO2012144784A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

본 발명은 인간 간-카르복실에스터라제 1을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도에 관한 것으로, 인간 간-카르복실에스터라제 1에 특이적으로 결합하여 조직, 혈액 등에서 인간 간-카르복실에스터라제 1 발현량을 객관적으로 분석하는데 사용할 수 있어 뇨 또는 혈액으로부터 간암을 간편하고 빠르게 진단할 수 있다.
PCT/KR2012/002911 2011-04-18 2012-04-17 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도 WO2012144784A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/112,411 US9116152B2 (en) 2011-04-18 2012-04-17 Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof
JP2014506322A JP5798679B2 (ja) 2011-04-18 2012-04-17 ヒト肝−カルボキシルエステラーゼ１を特異的に認識するモノクローナル抗体、前記抗体を生産するハイブリドーマ細胞株及びその用途
CN201280029813.2A CN104066749B (zh) 2011-04-18 2012-04-17 用于特异性识别人肝羧酸酯酶1的单克隆抗体、生成单克隆抗体的杂交瘤细胞株及其用途
EP12774256.7A EP2700650B1 (en) 2011-04-18 2012-04-17 Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20110035619 2011-04-18
KR10-2011-0035619 2011-04-18
KR10-2012-0034928 2012-04-04
KR1020120034928A KR101338517B1 (ko) 2011-04-18 2012-04-04 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도

Publications (2)

Publication Number Publication Date
WO2012144784A2 WO2012144784A2 (ko) 2012-10-26
WO2012144784A3 true WO2012144784A3 (ko) 2013-01-17

Family

ID=47285895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002911 WO2012144784A2 (ko) 2011-04-18 2012-04-17 인간 간-카르복실에스터라제 １을 특이적으로 인식하는 단일클론 항체, 상기 항체를 생산하는 하이브리도마 세포주 및 이의 용도

Country Status (6)

Country Link
US (1) US9116152B2 (ko)
EP (1) EP2700650B1 (ko)
JP (1) JP5798679B2 (ko)
KR (1) KR101338517B1 (ko)
CN (1) CN104066749B (ko)
WO (1) WO2012144784A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523077B1 (ko) * 2013-07-08 2015-05-26 포항공과대학교 산학협력단 pH 미터를 이용한 바이오 물질 검출 방법
CN103642825A (zh) * 2013-11-29 2014-03-19 湖南师范大学 一种重组hCE1蛋白的可溶性表达和纯化方法
CN112255061A (zh) * 2020-10-13 2021-01-22 南开大学 一种通过免疫沉淀分离和检测蛋白质的方法
CN116535512B (zh) * 2022-12-09 2024-03-15 中国医学科学院肿瘤医院 针对肝细胞癌患者的异常凝血酶原单克隆抗体的制备及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077479A2 (en) * 2007-12-17 2009-06-25 Novartis Ag Altering high-density lipoprotein levels through carboxylesterase 1 modulation
JP4288454B2 (ja) * 2000-09-04 2009-07-01 株式会社大塚製薬工場 薬物代謝の第ｉ相反応に関与する酵素の測定方法、そのためのプローブおよびキット
KR100975852B1 (ko) * 2008-03-14 2010-08-13 연세대학교 산학협력단 간-카르복실에스터라제 1 단백질과 특이적으로 결합하는 항체를 포함하는 간암 진단 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
EP0349578B2 (en) 1987-03-02 1998-10-28 Enzon Labs Inc. Organism carrying a Single Chain Antibody Domain at its surface.
AU605291B2 (en) 1987-03-20 1991-01-10 Micromet Ag Process for the purification of recombinant polypeptides
AU601273B2 (en) 1987-03-20 1990-09-06 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US7906637B2 (en) * 2006-06-23 2011-03-15 St. Jude Children's Research Hospital Compositions and methods for inducing or inhibiting activities of selected human cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4288454B2 (ja) * 2000-09-04 2009-07-01 株式会社大塚製薬工場 薬物代謝の第ｉ相反応に関与する酵素の測定方法、そのためのプローブおよびキット
WO2009077479A2 (en) * 2007-12-17 2009-06-25 Novartis Ag Altering high-density lipoprotein levels through carboxylesterase 1 modulation
KR100975852B1 (ko) * 2008-03-14 2010-08-13 연세대학교 산학협력단 간-카르복실에스터라제 1 단백질과 특이적으로 결합하는 항체를 포함하는 간암 진단 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NA, K. ET AL.: "Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma", PROTEOMICS, vol. 9, no. 16, 5 August 2009 (2009-08-05), pages 3989 - 3999, XP055117645 *

Also Published As

Publication number Publication date
JP2014512379A (ja) 2014-05-22
EP2700650B1 (en) 2018-05-30
US9116152B2 (en) 2015-08-25
US20140154699A1 (en) 2014-06-05
KR101338517B1 (ko) 2013-12-10
EP2700650A2 (en) 2014-02-26
WO2012144784A2 (ko) 2012-10-26
CN104066749B (zh) 2016-03-30
JP5798679B2 (ja) 2015-10-21
KR20120118412A (ko) 2012-10-26
EP2700650A4 (en) 2014-12-03
CN104066749A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
PH12021550083A1 (en) Human anti-tau antibodies
WO2011130434A3 (en) Antibodies that bind human cd27 and uses thereof
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
WO2009048537A3 (en) Humanized antibody
WO2011110642A3 (en) Monoclonal antibodies against c-met
MX345092B (es) Anticuerpos anti-tau humanos,.
EP3539988A3 (en) Monoclonal antibodies against her2
WO2009083009A3 (en) Monoclonal antibodies against cd32b
MX343858B (es) Anticuerpos anti-il-23.
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2010066803A3 (en) Human antibodies against human tissue factor
MY166776A (en) Humanised anti-ctla4 antibodies
EA201590247A1 (ru) Антитела к siglec-15
WO2011147982A3 (en) Monoclonal antibodies against her2 epitope
EA201400579A1 (ru) Антитела к il-36r
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
WO2011160119A3 (en) Anti-gd2 antibodies
AU2011343161A8 (en) Human anti-SOD1 antibodies
WO2011088385A3 (en) Compositions and methods for detecting cancer
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2008136774A8 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
AU2012323781A8 (en) Antibodies to CD1d

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201280029813.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12774256

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014506322

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012774256

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14112411

Country of ref document: US